- $19.98m
- $10.71m
- $57.57m
Brief: Aytu Biopharma Enters Into Stipulation Of Compromise And Settlement Related To Legal Action
U.S. STOCKS ON THE MOVE-Southwest Airlines, FedEx
Brief: Aytu Biopharma QTRLY Net Revenue Of $27.7 Million Driven By 34% Growth In Rx Segment
Aytu Biopharma Inc reports results for the quarter ended in September - Earnings Summary
Aytu Biopharma Inc expected to post a loss of 18 cents a share - Earnings Preview
Brief: Aytu Biopharma Announces Agreement With Avenue Venture Debt Fund To Extend Interest-Only Period Of Company’S Term Loan
Brief: Aytu Biopharma Inc - Announces Strategic Shift To Focus On Commercial Operations And Indefinite Suspension Of Clinical Development Programs
Aytu Biopharma Inc reports results for the quarter ended in June - Earnings Summary
Aytu Biopharma Inc expected to post a loss of 37 cents a share - Earnings Preview
Aytu BioPharma up on new patent for lead therapy
Brief: Aytu Biopharma Announces Addition Of Fourth Patent License For AR101
Brief: Aytu Biopharma announces issuance of its first patent for Ar101/Enzastaurin
Brief: Aytu Biopharma Announces Initiation Of AR101 Prevent Trial For Vascular Ehlers-Danlos Syndrome Treatment
Brief: Aytu Biopharma Inc Files Prospectus Relates To Resale Of 867,769 Shares Of Common Stock By Selling Stockholders
Brief: Aytu Biopharma Received Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard From Nasdaq
Aytu Biopharma Inc reports results for the quarter ended in March - Earnings Summary
Aytu Biopharma Inc expected to post a loss of 41 cents a share - Earnings Preview
Brief: Aytu Biopharma Reports Positive Preclinical Data For Healight Delivery Technology
Aytu Biopharma climbs on FDA "fast track" tag for rare genetic therapy